Clinical Trial Update: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CD19/22 CAR-T cells combined with a PD-1 inhibitor in relapsed/refractory B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19/22 CAR-T cells (chimeric antigen receptor T cells targeting CD19 and CD22)
• PD-1 inhibitor

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN